Caplin Point Laboratories was up 2.97% to Rs 377.95 at 14:50 IST on BSE after consolidated net profit surged 60.22% to Rs 22.56 crore on 23.44% growth in income from operations to Rs 95.72 crore in Q2 September 2016 over Q2 September 2015.
The result was announced after market hours yesterday, 9 November 2016.Meanwhile, the S&P BSE Sensex was up 328.18 points or 1.2% at 27,580.71.
On BSE, so far 29,000 shares were traded in the counter as against average daily volume of 49,000 shares in the past two weeks. The stock hit a high of Rs 399 and a low of Rs 376.10 so far during the day.
Caplin Point Laboratories is a pharmaceutical company, catering predominantly to emerging markets of Latin America and Africa.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app